Screener
Pacira BioSciences, Inc. PCRX Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Pacira BioSciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherOperatingIncomeExpenseNet.
The source filing: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:07 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028871
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Research and development | 28,072 | 25,342 |
| Selling, general and administrative | 93,944 | 86,776 |
| Amortization of acquired intangible assets | 14,322 | 14,322 |
| Other operating (gains) expenses, net | (2,277) | 6,187 |
| Total operating expenses | 170,474 | 166,933 |
| Income from operations | 6,902 | 1,990 |
| Other income (expense): | ||
| Interest income | 1,930 | 6,895 |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Pacira BioSciences, Inc.'s other operating expenses?
- Pacira BioSciences, Inc. (PCRX) reported other operating expenses of $2.28M in Q1 2026.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Pacira BioSciences, Inc.'s other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude